Clinical Trial Update: Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis [Phase 2]

View source ↗

Summary

A Phase 2 trial update reports on the tolerability and safety of adding ustekinumab to INGAP peptide in adults with Type 1 Diabetes Mellitus; the study has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• INGAP-Peptide (INGAP peptide)
• Stelara (ustekinumab)

Snippet

Sponsor: Jewish General Hospital | Conditions: Type 1 Diabetes Mellitus | Phase 2 | Status: COMPLETED